Kallyope Stock

kallyope.comBioTechFounded: 2015Funding to Date: $243.46MM

Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis by integrating cutting-edge technologies in sequencing, computational biology, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics that improve human health.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for Kallyope, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Nancy Thornberry
Chief Executive Officer & Board Member
Juha Lauren Ph.D
Chief Business Officer
Charles Zuker Ph.D
Co-Founder
Richard Axel MD
Co-Founder
Maximilian Lombardo
Senior Data Research Associate
Ann Weber Ph.D
Senior Vice President - Drug Discovery
Robert Anstey
Vice President, Business Development
Brett Lauring
Chief Medical Officer
Tom Maniatis Ph.D
Co-Founder & Board Member

Board Members

Amy Schulman JD
Polaris Partners
Joshua Wolfe
Lux Capital Management
Nancy Thornberry
Terry McGuire
Timothy Kutzkey Ph.D
The Column Group
Tom Maniatis Ph.D
Tony Evnin Ph.D
William Rieflin JD

Other companies like Kallyope in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$197.73MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Kallyope, a biotech company focused on identifying therapeutic opportunities involving the gut-brain axis, raised $21m in Series B financing